This seminar will review the regulatory requirements for investigating an OOS Investigation. The responsibilities of the analyst, the supervisor and QA will be discussed. A detailed flow chart will be used to help the attendees clearly understand the steps and the order in which they are to be performed. The structure of an Investigation report which properly documents the investigation will be discussed.
The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters. Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations.
Course Objectives:
• Learn the responsibilities of analysts and supervisors
• Listen to what the FDA looks for in terms of human errors
• Describe when a full investigation should be triggered
• Describe the frequency for re-testing and re-sampling
• Learn how to implement the corrective and preventive action plans (CAPA)
Course Outline:
Session 1:
Guidelines for Detecting an OOS or Atypical Result
• Definition Atypical or Out of Specification Result?
• Review of the FDA Guidance for Industry on Investigating OOS Test Results
o Phase I: Initial Laboratory Investigation
o Phase II: Full Scale Investigation
• Root Cause Analysis Methods
o 5 Whys
o Flow Charts
o Checklists
o Fishbone Diagrams
Session 2:
Testing the hypotheses regarding potential root causes
• Retesting
• Considering Other Batches
Session 3:
Developing a proper CAPA plan to address any Corrective Actions
• How to properly document findings
• Example of a proper OOS investigation write up
What You Get:
• Training Materials
• Live Q&A Session with our Expert
• Participation Certificate
• Access to Signup Community (Optional)
• Reward Points
Who Will Benefit:
• Quality Assurance Departments
• Quality Control Departments
• Research and Development Departments
• Regulatory Affairs Departments
• Compliance Departments
• Laboratory Staff
• Training Departments
• GMP auditors
• Consultants
6 Hours Virtual Seminar: Understanding and Controlling Biofilm - Preventing Water System Microbial Problems and Surviving Inspections
Get Instant Access 360 Minutes View Program |
Microbiological and Business Risk of not Testing Raw Materials for Microbial Presence
Get Instant Access 60 Minutes View Program |
Bioavailability and Bioequivalence Studies submitted in NDAs and INDs
Get Instant Access 90 Minutes View Program |
Veterinary Feed Directive (VFD) Final Rule – What you need to know?
Get Instant Access 60 Minutes View Program |
Packaging and Labeling for Commercial and Clinical Products
Get Instant Access 90 Minutes View Program |
Get Instant Access On-Demand Access
Preparing for the ICE Storm: What to Do During I 9 Audits and ICE Raids
Janette S. Levey
Human Resources
Get Instant Access On-Demand Access
OSHA Inspections and Investigations-How to Manage Them
Irwin Dobrushin
Environment Health and Safety | OSHA
Get Instant Access On-Demand Access
29 CFR 1904: OSHA's New Injury Recordkeeping E-Submission Rule
Occupational Safety and Health Administration
Get Instant Access On-Demand Access
Working with Excel Databases: Sort, Filter, Subtotal and More
Cathy Horwitz
Cross Industry | Skill Enhancement
Get Instant Access On-Demand Access
Writing Audit Reports
Jonnie T. Keith CIA, CFE, CGAP, CICA
Governance, Risk and Compliance
Get Instant Access On-Demand Access
BSA Reporting Requirements
Banking and Financial Services Industry
Get Instant Access On-Demand Access
Human Factors-Usability Based on ISO 62366
Medical Device | Diagnostic | Pharmaceutical | Biologics fields
Get Instant Access On-Demand Access
Chat GPT for Project Managers
Charles H. Paul
All FDA Regulated Industry